Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.

Yanagisawa T, Fukuokaya W, Hatakeyama S, Narita S, Muramoto K, Katsumi K, Takahashi H, Urabe F, Mori K, Tashiro K, Iwatani K, Shimomura T, Habuchi T, Kimura T.

Open source

DOI: 10.1002/pros.24813
Published: 2024-10-17
Container: Prostate
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/pros.24813,
  title = {Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.},
  author = {Yanagisawa T and  Fukuokaya W and  Hatakeyama S and  Narita S and  Muramoto K and  Katsumi K and  Takahashi H and  Urabe F and  Mori K and  Tashiro K and  Iwatani K and  Shimomura T and  Habuchi T and  Kimura T.},
  year = {2025},
  journal = {Prostate},
  doi = {10.1002/pros.24813},
  url = {https://doi.org/10.1002/pros.24813}
}

RIS

TY  - JOUR
TI  - Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.
AU  - Yanagisawa T
AU  -  Fukuokaya W
AU  -  Hatakeyama S
AU  -  Narita S
AU  -  Muramoto K
AU  -  Katsumi K
AU  -  Takahashi H
AU  -  Urabe F
AU  -  Mori K
AU  -  Tashiro K
AU  -  Iwatani K
AU  -  Shimomura T
AU  -  Habuchi T
AU  -  Kimura T.
PY  - 2025
JO  - Prostate
DO  - 10.1002/pros.24813
UR  - https://doi.org/10.1002/pros.24813
ER  -

APA

T, Y., W, F., S, H., S, N., K, M., K, K., H, T., F, U., K, M., K, T., K, I., T, S., T, H., & T., K. (2025). Comparison of abiraterone, enzalutamide, and apalutamide for metastatic hormone-sensitive prostate cancer: A multicenter study.. Prostate. https://doi.org/10.1002/pros.24813

Source records

europe-pmc · retrieved 2026-09-27T02:36:52.133Z